{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:20:42Z","timestamp":1787498442223,"version":"build-2736575974"},"reference-count":33,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2022,5,31]]},"abstract":"<jats:p>Background: Determining amyloid positivity is possible with cerebrospinal fluid and brain imaging of amyloid, but these methods are invasive and expensive. Objective: To relate plasma amyloid-\u03b2 (A\u03b2), measured using Single-molecule array (Simoatrademark) assays, to in vivo brain A\u03b2, measured using positron emission tomography (PET), examine the accuracy of plasma A\u03b2 to predict brain A\u03b2 positivity, and the relation of APOE \u025b4 with plasma A\u03b2. Methods: We performed a cross-sectional analysis in a cohort of 345 late middle-aged Hispanic men and women (age 64 years, 72% women). Our primary plasma variable was A\u03b242\/A\u03b240 ratio measured with Simoa. Brain A\u03b2 burden was measured as global SUVR with 18F-Florbetaben PET examined continuously and categorically. Results: Plasma A\u03b242\/A\u03b240 ratio was inversely associated with global A\u03b2 SUVR (\u03b2=\u200a\u20130.13, 95% Confidence Interval (CI): \u20130.23, \u20130.03; p\u200a=\u200a0.013) and A\u03b2 positivity (Odds Ratio: 0.59, 95% CI: 0.38, 0.91; p\u200a=\u200a0.016), independent of demographics and APOE \u025b4. ROC curves (AUC\u200a=\u200a0.73, 95% CI: 0.64, 0.82; p\u200a&lt;\u200a0.0001) showed that the optimal threshold for plasma A\u03b242\/A\u03b240 ratio in relation to brain A\u03b2 positivity was 0.060 with a sensitivity of 82.4% and specificity of 62.8%. APOE \u025b4 carriers had lower A\u03b242\/A\u03b240 ratio and a higher A\u03b2 positivity determined with the A\u03b242\/A\u03b240 ratio threshold of 0.060. Conclusion: Plasma A\u03b242\/A\u03b240 ratio assayed using Simoa is weakly correlated with in vivo brain amyloid and has limited accuracy in screening for amyloid positivity and for studying risk factors of brain amyloid burden when in vivo imaging is not feasible.<\/jats:p>","DOI":"10.3233\/jad-210391","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T12:08:56Z","timestamp":1650370136000},"page":"1229-1238","source":"Crossref","is-referenced-by-count":3,"title":["Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics"],"prefix":"10.1177","volume":"87","author":[{"given":"Brady","family":"Rippon","sequence":"first","affiliation":[{"name":"Department of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center (CUIMC), New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Palta","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center (CUIMC), New York, NY, USA"},{"name":"Department of Epidemiology, Joseph P. Mailman School of Public Health, CUIMC, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Tahmi","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center (CUIMC), New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greysi","family":"Sherwood","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center (CUIMC), New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Soto","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center (CUIMC), New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandino","family":"Cespedes","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center (CUIMC), New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanette","family":"Mesen","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center (CUIMC), New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengda","family":"He","sequence":"additional","affiliation":[{"name":"Department of Neurology, College of Physicians and Surgeons, CUIMC, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystal","family":"Laing","sequence":"additional","affiliation":[{"name":"Taub Institute for Research on Alzheimer\u2019s Disease and the Aging Brain, CUIMC, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Moreno","sequence":"additional","affiliation":[{"name":"Department of Neurology and Pharmacology\/Physiology, SUNY Downstate Medical Center, Brooklyn, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Teresi","sequence":"additional","affiliation":[{"name":"Research Division, Hebrew Home in Riverdale, Bronx, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qolamreza","family":"Razlighi","sequence":"additional","affiliation":[{"name":"Department of Radiology, Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Brickman","sequence":"additional","affiliation":[{"name":"Department of Neurology, College of Physicians and Surgeons, CUIMC, New York, NY, USA"},{"name":"Taub Institute for Research on Alzheimer\u2019s Disease and the Aging Brain, CUIMC, New York, NY, USA"},{"name":"Gertrude H. Sergievsky Center, CUIMC, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, M\u00f6lndal, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Luchsinger","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Physicians and Surgeons, Columbia University Irving Medical Center (CUIMC), New York, NY, USA"},{"name":"Department of Epidemiology, Joseph P. Mailman School of Public Health, CUIMC, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-210391_ref1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: An updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-210391_ref2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-210391_ref3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-210391_ref4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-210391_ref5","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jama.2015.4669","article-title":"Prevalence of amyloid PET positivity in dementia syndromes: A meta-analysis","volume":"313","author":"Ossenkoppele","year":"2015","journal-title":"JAMA"},{"key":"10.3233\/JAD-210391_ref6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.dadm.2016.05.005","article-title":"Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders","volume":"3","author":"Andreasson","year":"2016","journal-title":"Alzheimers Dementia (Amst)"},{"key":"10.3233\/JAD-210391_ref7","doi-asserted-by":"crossref","first-page":"e28263","DOI":"10.1371\/journal.pone.0028263","article-title":"Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid \u03b2 levels in humans","volume":"6","author":"Zetterberg","year":"2011","journal-title":"PLoS One"},{"key":"10.3233\/JAD-210391_ref8","doi-asserted-by":"crossref","first-page":"e2086","DOI":"10.1212\/WNL.0000000000010707","article-title":"Apolipoprotein E genotype and in-vivo amyloid burden in middle-aged hispanics","volume":"95","author":"Palta","year":"2020","journal-title":"Neurology"},{"key":"10.3233\/JAD-210391_ref9","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3233\/JAD-200232","article-title":"Pre-diabetes, but not type 2 diabetes, is related to brain amyloid in late middle-age","volume":"75","author":"Luchsinger","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-210391_ref10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/PSY.0000000000000208","article-title":"Glycemia, diabetes status, and cognition in hispanic adults aged 55-64 years","volume":"77","author":"Luchsinger","year":"2015","journal-title":"Psychosom Med"},{"key":"10.3233\/JAD-210391_ref11","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.dadm.2019.05.007","article-title":"Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition","volume":"11","author":"Risacher","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-210391_ref12","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JAD-210391_ref13","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jalz.2019.03.009","article-title":"Plasma amyloid beta 40\/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer\u2019s disease","volume":"15","author":"Vergallo","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-210391_ref14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/2211068215589580","article-title":"The Simoa HD-1 Analyzer: A novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing","volume":"21","author":"Wilson","year":"2015","journal-title":"J Lab Autom"},{"key":"10.3233\/JAD-210391_ref15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/alzrt163","article-title":"Plasma tau levels in Alzheimer\u2019s disease","volume":"5","author":"Zetterberg","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"10.3233\/JAD-210391_ref16","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3233\/JAD-170773","article-title":"The past and the future of Alzheimer\u2019s disease fluid biomarkers","volume":"62","author":"Blennow","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-210391_ref17","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma beta-amyloid in Alzheimer\u2019s disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-210391_ref18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40120-017-0074-8","article-title":"Amyloid beta and tau as Alzheimer\u2019s disease blood biomarkers: Promise from new technologies","volume":"6","author":"Lue","year":"2017","journal-title":"Neurol Ther"},{"key":"10.3233\/JAD-210391_ref19","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.25334","article-title":"Plasma amyloid as prescreener for the earliest Alzheimer pathological changes","volume":"84","author":"Verberk","year":"2018","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-210391_ref20","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2967\/jnumed.119.228510","article-title":"A fully automatic technique for precise localization and quantification of Amyloid-\u03b2 PET scans","volume":"60","author":"Tahmi","year":"2019","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-210391_ref22","doi-asserted-by":"crossref","unstructured":"(2019) 2019 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 15, 321\u2013387.","DOI":"10.1016\/j.jalz.2019.01.010"},{"key":"10.3233\/JAD-210391_ref23","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysisprevalence of cerebral amyloid pathology in persons without dementiaprevalence of cerebral amyloid pathology in persons without dementia","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"key":"10.3233\/JAD-210391_ref24","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1148\/radiology.148.3.6878708","article-title":"A method of comparing the areas under receiver operating characteristic curves derived from the same cases","volume":"148","author":"Hanley","year":"1983","journal-title":"Radiology"},{"key":"10.3233\/JAD-210391_ref25","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"10.3233\/JAD-210391_ref26","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/JTO.0b013e3181ec173d","article-title":"Receiver operating characteristic curve in diagnostic test assessment","volume":"5","author":"Mandrekar","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.3233\/JAD-210391_ref27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neulet.2011.09.049","article-title":"Alterations in the blood brain barrier in ageing cerebral cortex in relationship to Alzheimer-type pathology: A study in the MRC-CFAS population neuropathology cohort","volume":"505","author":"Viggars","year":"2011","journal-title":"Neurosci Lett"},{"key":"10.3233\/JAD-210391_ref28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.neuron.2014.12.032","article-title":"Blood-brain barrier breakdown in the aging human hippocampus","volume":"85","author":"Montagne","year":"2015","journal-title":"Neuron"},{"key":"10.3233\/JAD-210391_ref29","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fneur.2015.00236","article-title":"Blood-based proteomic biomarkers of Alzheimer\u2019s disease pathology","volume":"6","author":"Baird","year":"2015","journal-title":"Front Neurol"},{"key":"10.3233\/JAD-210391_ref30","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1212\/WNL.0000000000013211","article-title":"Validation of plasma amyloid-\u03b2 42\/40 for detecting Alzheimer disease amyloid plaques","volume":"98","author":"Li","year":"2022","journal-title":"Neurology"},{"key":"10.3233\/JAD-210391_ref31","doi-asserted-by":"crossref","first-page":"fcz038","DOI":"10.1093\/braincomms\/fcz038","article-title":"Relationship of amyloid-\u03b21\u201342 in blood and brain amyloid: Ginkgo Evaluation of Memory Study","volume":"2","author":"Lopez","year":"2019","journal-title":"Brain Commun"},{"key":"10.3233\/JAD-210391_ref32","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-210391_ref33","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","article-title":"Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status","volume":"76","author":"Palmqvist","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-210391_ref34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-210391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:05:53Z","timestamp":1777370753000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-210391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":33,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jad-210391","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]}}}